Who are ibuprofen; pseudoephedrine HCl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Naproxen Sodium & Pseudoephedrine HCl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibuprofen-pseudoephedrine-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ibuprofen; pseudoephedrine HCl — Competitive Intelligence Brief

ibuprofen; pseudoephedrine HCl (ibuprofen; pseudoephedrine HCl) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + sympathomimetic decongestant combination. Area: Pain Management / Cold & Allergy.

marketed NSAID + sympathomimetic decongestant combination COX-1/COX-2 (ibuprofen); alpha-adrenergic receptors (pseudoephedrine) Pain Management / Cold & Allergy Small molecule Live · refreshed every 30 min

Target snapshot

ibuprofen; pseudoephedrine HCl (ibuprofen; pseudoephedrine HCl) — Johnson & Johnson Consumer and Personal Products Worldwide. Ibuprofen reduces pain and inflammation by inhibiting cyclooxygenase enzymes, while pseudoephedrine constricts blood vessels in the nasal passages to relieve congestion.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ibuprofen; pseudoephedrine HCl TARGET	ibuprofen; pseudoephedrine HCl	Johnson & Johnson Consumer and Personal Products Worldwide	marketed	NSAID + sympathomimetic decongestant combination	COX-1/COX-2 (ibuprofen); alpha-adrenergic receptors (pseudoephedrine)
Naproxen Sodium & Pseudoephedrine HCl	Naproxen Sodium & Pseudoephedrine HCl	Dr. Reddy's Laboratories Limited	marketed	NSAID + sympathomimetic decongestant combination	COX-1/COX-2 (naproxen); alpha-1 adrenergic receptor (pseudoephedrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + sympathomimetic decongestant combination class)

Dr. Reddy's Laboratories Limited · 1 drug in this class
Johnson & Johnson Consumer and Personal Products Worldwide · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ibuprofen; pseudoephedrine HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/ibuprofen-pseudoephedrine-hcl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab